Report indicates shift in strategy

A report released by Best Practices indicates that leading pharma and biopharmaceutical companies are rethinking their publication strategies, in light of new transparency guidelines.

“Traditional, global peer-reviewed journals remain the first choice of most companies at all phases of product development, but companies are increasingly exploring alternative media for scientific publications—50% of benchmark participants said they will be increasing the percentage of articles they submit to alternative media, such as e-journals, compared with 36% increasing submission to peer-reviewed journals,” said Martha Haswell, senior research analyst at Best Practices. 
You must be a registered member of MMM to post a comment.
close

Next Article in Features


Email Newsletters


Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.